Equities analysts expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to post $734.59 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for IDEXX Laboratories’ earnings, with the lowest sales estimate coming in at $726.30 million and the highest estimate coming in at $743.55 million. IDEXX Laboratories posted sales of $626.34 million during the same quarter last year, which suggests a positive year over year growth rate of 17.3%. The firm is scheduled to announce its next earnings report before the market opens on Tuesday, May 4th.
On average, analysts expect that IDEXX Laboratories will report full year sales of $3.09 billion for the current year, with estimates ranging from $3.08 billion to $3.11 billion. For the next fiscal year, analysts forecast that the firm will report sales of $3.41 billion, with estimates ranging from $3.39 billion to $3.44 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that follow IDEXX Laboratories.
IDEXX Laboratories (NASDAQ:IDXX) last issued its earnings results on Tuesday, May 4th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.63. The company had revenue of $777.71 million for the quarter, compared to analysts’ expectations of $738.43 million. IDEXX Laboratories had a net margin of 19.20% and a return on equity of 198.91%. The firm’s revenue was up 24.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.29 EPS.
In other news, Director M Anne Szostak sold 11,876 shares of the stock in a transaction on Thursday, February 4th. The stock was sold at an average price of $489.71, for a total value of $5,815,795.96. Following the sale, the director now directly owns 5,974 shares of the company’s stock, valued at $2,925,527.54. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 13,868 shares of the firm’s stock in a transaction on Wednesday, February 17th. The shares were sold at an average price of $537.21, for a total value of $7,450,028.28. Following the transaction, the chief executive officer now owns 68,090 shares of the company’s stock, valued at $36,578,628.90. The disclosure for this sale can be found here. Insiders have sold 34,143 shares of company stock valued at $17,729,819 in the last ninety days. Insiders own 2.53% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in IDXX. BlackRock Inc. increased its position in shares of IDEXX Laboratories by 1.7% during the fourth quarter. BlackRock Inc. now owns 7,889,592 shares of the company’s stock valued at $3,943,772,000 after acquiring an additional 129,494 shares in the last quarter. Alliancebernstein L.P. raised its stake in shares of IDEXX Laboratories by 2.5% in the fourth quarter. Alliancebernstein L.P. now owns 1,387,981 shares of the company’s stock worth $693,810,000 after purchasing an additional 34,000 shares during the last quarter. Brown Advisory Inc. lifted its holdings in shares of IDEXX Laboratories by 16.6% during the fourth quarter. Brown Advisory Inc. now owns 857,183 shares of the company’s stock valued at $428,480,000 after purchasing an additional 122,300 shares in the last quarter. Nuveen Asset Management LLC lifted its holdings in shares of IDEXX Laboratories by 17.0% during the fourth quarter. Nuveen Asset Management LLC now owns 723,779 shares of the company’s stock valued at $361,796,000 after purchasing an additional 104,982 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of IDEXX Laboratories by 0.5% during the fourth quarter. Bank of New York Mellon Corp now owns 718,949 shares of the company’s stock valued at $359,381,000 after buying an additional 3,268 shares during the last quarter. Institutional investors and hedge funds own 85.06% of the company’s stock.
Shares of IDXX traded down $23.00 during mid-day trading on Thursday, hitting $526.88. 598,842 shares of the company’s stock traded hands, compared to its average volume of 444,997. The company has a quick ratio of 1.24, a current ratio of 1.65 and a debt-to-equity ratio of 1.93. The firm has a market capitalization of $45.12 billion, a P/E ratio of 91.79, a PEG ratio of 4.55 and a beta of 0.88. The business’s 50-day moving average price is $512.40 and its 200-day moving average price is $489.14. IDEXX Laboratories has a 1 year low of $271.01 and a 1 year high of $573.99.
IDEXX Laboratories Company Profile
IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management.
Recommended Story: Current Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.